SES Announces Annual General Meeting Voting Results
SES S.A. (“SES” or the “Company”) held the Company’s Annual General Meeting (“AGM”) at its headquarters in Betzdorf, Luxembourg, yesterday.
The shareholders have voted all resolutions in accordance with the recommendations made by SES’s Board of Directors, notably the company’s 2024 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total amount includes the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) already paid to shareholders on 17 October 2024. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on 17 April 2025.
Also as recommended by the Board of Directors, the shareholders approved the appointments of Mrs Ellen Lord and Mr John Shaw to the Board of Directors and the non-binding agenda item received from Atlas Infrastructure Partners regarding capital returns.
“The outcome of the AGM is the result of SES’s ongoing commitment to productive shareholder engagement, ensuring alignment and confidence in the Company’s long-term strategic direction,” said Adel Al-Saleh, CEO of SES. “We greatly appreciate the constructive collaboration and have benefited from our various shareholder discussions. We welcome Ellen Lord and John Shaw to our Board of Directors as we continue to drive SES towards its next phase of success.”
Shareholders also re-elected Mr Peter van Bommel, Mrs Fabienne Bozet and Mrs Françoise Thoma as directors for another three-year mandate.
Following the AGM, the Board of Directors elected Mr Frank Esser as Chairperson for a period of one year and both, Mrs Anne-Catherine Ries and Mr Peter van Bommel as Vice-Chairperson also for a period of one year.
Detailed results on all matters voted on at the AGM will be available on the company’s webpage in due course at: https://www.ses.com/company/investors/shareholder-information/general-meeting-shareholders.
The 2024 Annual Report is available for download at: https://www.ses.com/company/investors/reports-and-presentations
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About SES
SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous earth orbit (GEO) fleet and medium earth orbit (MEO) constellation of satellites, offering a combination of global coverage and high-performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The Company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403294388/en/
Contacts
For further information please contact:
Christian Kern
Investor Relations
Tel: +352 710 725 7787
christian.kern@ses.com
Suzanne Ong
Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICD 2025: New data demonstrate Nemluvio ® ’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years.1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617336479/en/ “These promising data go even further in highlighting the extensive benefits of Nemluvio. As this treatment becomes available in more countries around the world, it’s highly encouraging to see its robust evidence base continue to expand and strengthen.” BALDO SCASSELLATI SFORZOLINI, M.D., PHD. GLOBAL HEAD OF RESEARCH & DEVELOPMENT GALDERMA Prurigo nodularis is a chronic, de
LabPMM ® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 07:30:00 EEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 04:30:00 EEST | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contributing to a safe and secure Smart Society. [About Laxton] Laxton develops ID authentication services using biometric information
DNP: Operational Launch of 2,500 mm-Width Coating Line to Enhance Production Capacity by 15%18.6.2025 04:20:00 EEST | Press release
Dai Nippon Printing Co., Ltd. (DNP) is pleased to announce the September operational launch of a coating device compatible with 2,500 mm-width high functional optical film at our Mihara Plant in Hiroshima Prefecture. The operational launch of the second wide coating device comes in response to market and consumer needs, and will boost production capacity by more than 15% on an area basis. With the increased capacity, DNP will accommodate the demand for high functional optical film for 65-inch large-screen TVs, with horizontal and vertical dimensions of 1,436.4 mm x 809.0 mm, which are expected to increase at a compound annual growth rate (CAGR) of approximately 6% between 2025 and 20301 on an area basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613720341/en/ Image of Mihara Plant [Features] Facilitates the efficient manufacture, or imposition, of high function optical film for 65 inch large screen displays. Designed
Alipay Enables In-Store Payment Functionality in China for AR Glasses in Collaboration with Rokid to Build Immersive Commerce18.6.2025 03:27:00 EEST | Press release
Rokid, a pioneer in augmented reality (AR), today launched Rokid Glasses, its latest AR device. In China, the product supports in-store payments facilitated by Alipay’s digital payment technology and multidimensional risk control solution for AR glasses, providing a seamless and secure payment experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617845457/en/ Rokid partners with Alipay to launch China’s first AR glasses with in-store payment capabilities. According to Rokid, the product will begin rolling out to users starting in June 2025, with over 250,000 units already ordered. How Payment via AR Glasses Works: Users link their Alipay account via the Rokid app and enable voice verification. In stores, they say: “Rokid, pay 10 RMB.” The glasses scan the merchant’s Alipay QR code. Users confirm by voice, with payment details shown on the display. Advantages of Payment via AR Glasses: Transactions complete in second
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom